Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,168,049
  • Shares Outstanding, K 101,475
  • Annual Sales, $ 63,520 K
  • Annual Income, $ -376,740 K
  • EBIT $ -466 M
  • EBITDA $ -467 M
  • 60-Month Beta 2.07
  • Price/Sales 52.62
  • Price/Cash Flow N/A
  • Price/Book 3.72

Options Overview Details

View History
  • Implied Volatility 96.39% (+7.44%)
  • Historical Volatility 79.18%
  • IV Percentile 89%
  • IV Rank 65.82%
  • IV High 119.34% on 05/06/25
  • IV Low 52.20% on 08/06/25
  • Expected Move (DTE 34) 4.75 (15.22%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 821
  • Volume Avg (30-Day) 866
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 36,776
  • Open Int (30-Day) 32,657
  • Expected Range 26.47 to 35.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.13
  • Number of Estimates 5
  • High Estimate -0.90
  • Low Estimate -1.24
  • Prior Year -1.09
  • Growth Rate Est. (year over year) -3.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.53 +22.29%
on 12/17/25
36.44 -14.32%
on 01/12/26
+4.46 (+16.67%)
since 12/16/25
3-Month
20.23 +54.33%
on 11/20/25
36.44 -14.32%
on 01/12/26
+5.43 (+21.05%)
since 10/16/25
52-Week
13.52 +130.83%
on 04/07/25
36.44 -14.32%
on 01/12/26
+7.82 (+33.42%)
since 01/16/25

Most Recent Stories

More News
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application...

BEAM : 31.22 (-2.59%)
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 31.22 (-2.59%)
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Updated Data from 31 Adult and Adolescent SCD Patients  Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to

BEAM : 31.22 (-2.59%)
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 31.22 (-2.59%)
2 Stocks to Buy Now to Profit from the Rise of Robotics

Investors betting on the future of automation in high-tech manufacturing would do well to keep these two stocks on their radar.

BEAM : 31.22 (-2.59%)
LCID : 10.12 (+0.70%)
ROK : 415.52 (-1.33%)
BA : 247.68 (-0.02%)
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026...

BEAM : 31.22 (-2.59%)
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 31.22 (-2.59%)
H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics today and set a price target of $80.00. The company’s shares closed yesterday at $27.87.Elevate Your Investing Strategy:...

BEAM : 31.22 (-2.59%)
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 31.22 (-2.59%)
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 31.22 (-2.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 33.51
2nd Resistance Point 32.87
1st Resistance Point 32.05
Last Price 31.22
1st Support Level 30.59
2nd Support Level 29.95
3rd Support Level 29.13

See More

52-Week High 36.44
Last Price 31.22
Fibonacci 61.8% 27.69
Fibonacci 50% 24.98
Fibonacci 38.2% 22.28
52-Week Low 13.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar